Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:59 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1489–1512 of 7,248 matching trials from the live ClinicalTrials.gov search.

Filters: Detroit, Michigan Clear all

Conditions: Stage III Uterine Corpus Leiomyosarcoma AJCC v8, Stage IV Uterine Corpus Leiomyosarcoma AJCC v8, Uterine Corpus Leiomyosarcoma
Interventions: Computed Tomography, Core Biopsy, Magnetic Resonance Imaging, Olaparib, Temozolomide; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 15
States / cities: Phoenix, Arizona • Palo Alto, California • Aurora, Colorado + 11 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Placebo 0.04 mL twice daily, Placebo 0.04 mL once daily, Placebo 0.08 mL once daily, B - Exenatide 10 mcg twice daily, C - Exenatide 10 mcg once daily, Exenatide 20 mcg once daily; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 23
States / cities: La Jolla, California • San Diego, California • Washington D.C., District of Columbia + 19 more

Conditions: Type 1 Diabetes
Interventions: Fit Families plus Standard Medical Care; Behavioral
Lead sponsor: Wayne State University; Other
Eligibility: 10 Years to 17 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Cachexia, Lymphoma, Lymphoproliferative Disorder, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Juven, Non-Juven Supplement; Dietary Supplement
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 17 Years to 120 Years
Enrollment: 472 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2009
U.S. locations: 230
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 181 more

Conditions: Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Interventions: NTLA-2001, Placebo; Biological · Drug
Lead sponsor: Intellia Therapeutics; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 39
States / cities: Tucson, Arizona • Los Angeles, California • Palo Alto, California + 30 more

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2001
U.S. locations: 83
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 53 more

Conditions: HER2-Positive Breast Carcinoma, Invasive Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
Interventions: Laboratory Biomarker Analysis, Lapatinib Ditosylate, Stereotactic Radiosurgery, Whole-Brain Radiotherapy; Other · Drug · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2022
U.S. locations: 292
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 210 more

Conditions: Children, Adolescents
Interventions: Moderate Intensity Exercise, Light Intensity Stretching, Seated Meditation; Behavioral
Lead sponsor: Wayne State University; Other
Eligibility: 9 Years to 17 Years
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Intermittent Claudication, Peripheral Artery Disease
Interventions: Placebo, 375 mg CK-2017357, 500 mg CK-2017357; Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 40 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 14
States / cities: Phoenix, Arizona • Santa Ana, California • Stanford, California + 11 more

Conditions: Stress, Emotional, Sleep Disturbance
Interventions: Sleep Hygiene Intervention, Non-behavioral Sleep Education; Behavioral
Lead sponsor: Wayne State University; Other
Eligibility: 18 Years to 24 Years
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Endocarditis
Interventions: CF-301, Placebo; Biological · Drug
Lead sponsor: ContraFect; Industry
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 31
States / cities: Birmingham, Alabama • Sacramento, California • Sylmar, California + 25 more

Conditions: HER2+ Metastatic Breast Cancer (MBC)
Interventions: neratinib, capecitabine, lapatinib; Drug
Lead sponsor: Puma Biotechnology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 621 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 79
States / cities: Chandler, Arizona • Gilbert, Arizona • Mesa, Arizona + 56 more

Conditions: HIV Infection
Interventions: Highly active antiretroviral therapy (HAART); Drug
Lead sponsor: International Maternal Pediatric Adolescent AIDS Clinical Trials Group; Network
Eligibility: 18 Years and older · Female only
Enrollment: 1,653 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 26
States / cities: Alhambra, California • Los Angeles, California • San Diego, California + 20 more

Conditions: Abscess, Wound Infection, Surgical Site Infection, Cellulitis
Interventions: Dalbavancin, Vancomycin / Linezolid; Drug
Lead sponsor: Durata Therapeutics Inc., an affiliate of Allergan plc; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 573 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 55
States / cities: Anaheim, California • Azusa, California • Bellflower, California + 50 more

Conditions: Diabetes Mellitus
Interventions: Rosuvastatin, Atorvastatin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 353 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 29
States / cities: Avondale, Arizona • Phoenix, Arizona • Jonesboro, Arkansas + 26 more

Conditions: AL Amyloidosis
Interventions: Bendamustine, Dexamethasone; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 6
States / cities: Boston, Massachusetts • Detroit, Michigan • New York, New York

Conditions: Congestive Heart Failure
Interventions: AC2592, placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 29
States / cities: Beverly Hills, California • Mission Viejo, California • New Haven, Connecticut + 26 more

Conditions: Brain Cancer
Interventions: Nivolumab, Temozolomide, Radiotherapy; Drug · Radiation
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 560 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 37
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 31 more

Conditions: Diabetes Mellitus, Type 2
Interventions: AC2993, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 16 Years to 75 Years
Enrollment: 336 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 129
States / cities: Anniston, Alabama • Birmingham, Alabama • Eclectic, Alabama + 99 more

Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: flow cytometry, immunoenzyme technique, laboratory biomarker analysis; Other
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: HIV, PrEP
Interventions: Not listed
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 15 Years to 22 Years · Male only
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 11
States / cities: Los Angeles, California • Miami, Florida • Tampa, Florida + 8 more

Conditions: Acute Coronary Syndrome
Interventions: Dalcetrapib, Placebo; Drug
Lead sponsor: DalCor Pharmaceuticals; Industry
Eligibility: 45 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 186
States / cities: Alexander City, Alabama • Birmingham, Alabama • Fairhope, Alabama + 163 more

Conditions: Melanoma
Interventions: Talimogene Laherparepvec, Pembrolizumab, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 95 Years
Enrollment: 713 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 41
States / cities: Birmingham, Alabama • Mobile, Alabama • Beverly Hills, California + 32 more

Conditions: Breast Cancer
Interventions: cyclophosphamide, docetaxel, doxorubicin; Drug
Lead sponsor: NSABP Foundation Inc; Network
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 5,351 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2012
U.S. locations: 146
States / cities: Huntsville, Alabama • Anchorage, Alaska • Phoenix, Arizona + 123 more

Search by objective public record fields.

A Phase II Clinical Trial Evaluating the Combination of Olaparib and Temozolomide for the Treatment of Advanced Uterine Leiomyosarcoma

Effect of Exenatide Monotherapy on Glucose Control in Subjects With Type 2 Diabetes Mellitus

Home-Based Interventions for Adolescents With Type 1 Diabetes

Comparison of Nutritional Supplements in Preventing Weight Loss in Patients With Cancer

MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)

S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer

Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer

Exercise and Endocannabinoids for Brain and Mental Health

A Study of CK-2017357 in Patients With Peripheral Artery Disease and Symptomatic Claudication

Sleep Hygiene Intervention on Undergraduate Students' Sleep and Stress

Safety, Efficacy and Pharmacokinetics of CF-301 vs. Placebo in Addition to Antibacterial Therapy for Treatment of S. Aureus Bacteremia

A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting

IMPAACT 1077HS: Examining Benefits of HAART Continuation in Postpartum Women

Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections

Prospective Evaluation of Proteinuria and Renal Function in Diabetic Patients With Progressive Renal Disease

Bendamustine and Dexamethasone in Patients With Relapsed AL Amyloidosis

PROCLAIM: Effect of AC2592 Administered by Continuous Subcutaneous Infusion in Subjects With Advanced Chronic Congestive Heart Failure

An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)

Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With Metformin

Studying T Cells in Blood and Bone Marrow Samples From Patients With Multiple Myeloma

Self-Consent for PrEP Perspectives

Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS

Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma

Combination Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA (cT1-3, N0-1, M0) Breast Cancer and Positive Axillary Lymph Nodes